PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rivaroxaban - VTE prevention post hip/knee replacement

PAD Profile : Rivaroxaban - VTE prevention post hip/knee replacement

Keywords :
VTE prophylaxis, venous thromboembolism,NOACs, anticoagulant cards, anticoagulant alert cards, SWLEOC guidelines
Brand Names Include :
Xarelto

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
01 June 2016
Surrey Medicines Commissioners Group
Surrey Medicines Commissioning Group recommend that patients prescribed all types of anticoagulants (warfarin and NOACs) should be given an anticoagulant alert card to carry with them. For patients taking NOACs, the card should be annotated on the reverse in the “Therapeutic range (INR)” box with the words “not applicable” or “not required for this drug”. The cards are available for practices to order through usual NHS stationery supply routes. See an example of the Anticoagulant Alert Card in the document below
20 May 2009
Surrey Medicines Commissioners Group
The committee confirmed that rivaroxaban should be considered a hospital only RED drug for the prevention of venous thromboembolism after total hip or total knee replacement in adults - the full treatment course should be given by the acute trust provider

Associated BNF Codes

02. Cardiovascular System
02.08.02. Oral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More